Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion

Journal of the American College of Cardiology

Volumn 30, Issue 2, 1997, Pages 343-349

  Shapiro, Shelley M ^a,b   Oudiz, Ronald J ^a,b,c   Cao, Tiesheng ^d   Romano, Matthew A ^e   Beckmann, X Joy ^b   Georgiou, Demitrios ^f   Mandayam, Sarathy ^a   Ginzton, Leonard E ^a,b   Brundage, Bruce H ^a,b  

^a St John's Cardiovascular Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Breast Cancer Consultation Service St Mary Hospital and Medical Center Pathology   (United States)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Gramercy Cardiol Diagn Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; HYDRALAZINE; NITROPRUSSIDE SODIUM; PROSTACYCLIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIAC OUTPUT; CHILD; ECHOCARDIOGRAPHY, DOPPLER; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 0030856433     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00187-3     Document Type: Article

References (12)

1. Glanville AR, Burke MB, Theodore J, Robin ED. Primary pulmonary hypertension length of survival in patients referred for heart-lung transplantation . Chest. 91:1987;675-681.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky DH, Brundage BH. Survival in patients with primary pulmonary hypertension results from a National Prospective Registry . Ann Intern Med. 115:1991;343-348.
3. Weir E, Rubin L, Ayers S. The acute administration of vasodilators in primary pulmonary hypertension experience from the National Institutes of Health registry on primary pulmonary hypertension . Am Rev Respir Dis. 140:1980;1623-1630.
4. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy . Circulation. 76:1987;135-141.
5. Rubin LJ, Mendoza J, Hood M, et al. Treatment of pulmonary hypertension with infusion of prostacyclin (epoprostenol). Ann Intern Med. 112:1990;485-491.
6. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 121:1994;409-415.
7. Barst RJ, Lewis RJ, Long WA, McGoon MD, Rich S, Badesch DB. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy in primary pulmonary hypertension. New Engl J Med. 334:1996;296-301.
8. Zoghbi WA, Quinones MA. Determination of cardiac output by Doppler echocardiography a critical appraisal . Herz. 11:1986;258-268.
9. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 70:1984;657.
10. Hatle L, Angelsen B. Doppler Ultrasound in Cardiology Physical Principles and Clinical Applications . 1985;23 Lea and Febiger, Philadelphia.
11. Raffy O, Azarian R, Brenot F, Parent F, Sitbon L, Simmoneau G. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 93:1996;484-488.
12. Rich S, Kaufmann E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 327:1992;76-81.